Select Page

STAT Plus: Sage’s new antidepressant faces major setback in new study

STAT Plus: Sage’s new antidepressant faces major setback in new study



An experimental pill from Sage Therapeutics that aimed to treat depression more rapidly than existing drugs failed its first large study in patients in major depression, a significant setback for the firm.

The drug, called SAGE-217, did not show a statistically significant, anti-depressive benefit compared with a placebo.

Continue to STAT Plus to read the full story…



Source link

About The Author

Leave a reply

Your email address will not be published. Required fields are marked *